Mylan, Ethypharm Strike Deal In FazaClo Patent Spat

Law360, New York (January 18, 2011, 5:44 PM ET) -- Mylan Pharmaceuticals Inc. has agreed to end its declaratory judgment suit against Ethypharm SA over the schizophrenia drug FazaClo, with the drug companies entering a stipulated judgment that Mylan's generic medication would not infringe Ethypharm's patent.

Judge Leonard P. Stark signed off on the final judgment in the U.S. District Court for the District of Delaware on Thursday, declaring that Mylan's products that are the subject of its abbreviated new drug application for a generic version of FazaClo do not infringe any claim of U.S. Patent...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers